Wednesday, February 19, 2025 7:33:39 PM
"massaged into just what the EMA wants to see". And we were right in the middle of that time period. Asked to File for Full Approval Dec 23 rapporteurs appointed I think it was in Jan or Feb 2024. So they asked we answered and the filing was accepted late Dec 2024. We will have all the OLE compiled and will present soon at some conference. And am sure they will have also sent all off to the rapporteurs. From the leaks we already know the OLE is good. Some up to 4 years and some up to NINE YEARS on 2-73. 74 still remain on the drug. Our efficacy is better than any of the MAB's We don't have any safety issues. What little bit we had has been fixed by slower Titration. Plus give patients the pill before bedtime. Very little dizziness.
A little bit about someone else. Good friend of my Brother... his wife was in the Biogen Trial. Included the stop during covid. Then the restart. Then came the day they said you can't have any more of the drug. She had of course continued to go downhill during but not as fast as a normal only on SOC drug. Well as soon as she was off the drug it was a rapid drop. She can't remember her husbands name. At least she never had the brain bleed.
Last bit for this evening. Today a total of 677,000 shares traded. 78,000 of them traded as MOC order. Easy for whoever is getting the shares 1/2Million a week. All we know is 4th qtr 2024 we went from 31% to 42% tute ownership. Now half way through Q1 2025 and we won't know what happened until May 15th.
John k9uwa
A little bit about someone else. Good friend of my Brother... his wife was in the Biogen Trial. Included the stop during covid. Then the restart. Then came the day they said you can't have any more of the drug. She had of course continued to go downhill during but not as fast as a normal only on SOC drug. Well as soon as she was off the drug it was a rapid drop. She can't remember her husbands name. At least she never had the brain bleed.
Last bit for this evening. Today a total of 677,000 shares traded. 78,000 of them traded as MOC order. Easy for whoever is getting the shares 1/2Million a week. All we know is 4th qtr 2024 we went from 31% to 42% tute ownership. Now half way through Q1 2025 and we won't know what happened until May 15th.
John k9uwa
Bullish
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
